Renal Dysfunction Flashcards
Pain medications to
-avoid
-use in CKD
NSAIDs
Strong opioids - adverse effects more pronounced in renal impairment
-can use low-dose fentanyl if codeine not an option, no active metabolites excreted through kidneys
Weak opioids - can consider, but adverse effects can be more pronounced in renal impairment
-codeine
Causes of drug-induced nephrotoxicity
Direct nephrotoxicity
Aminoglycosides - ATN
Amphotericin
Cytotoxics
Insecticides/herbicides
Cocaine
Volume depletion
-diuretics
Hypoperfusion
-NSAIDs/COX2inh
Interstitial damage
Lithium
Vasoconstrictors
Immunosuppressants - ischemia
-ciclosporin, tacrolimus
Radioconstrast
Nephrotoxic pathological states
Hypoperfusion
Sepsis - endotoxins, inflammatory markers => damage vascular endothelium => thrombosis
Rhabdomyolysis
Hepatorenal syndrome - association between ESLD + renal vasoconstriction
When should creatinine clearance be used over eGFR
Older adults
Patients on nephrotoxics
Extremes of muscle mass/weight
Medication with a narrow therapeutic index
Patients on DOACs
Used to adjust the drug dosing
Pharmacokinetic considerations to make in CKD
Elimination half life - prolonged in CKD if drug is predominantly excreted by the kidney
-accumulates quickly unless dosing regimen also prolonged
Adjust drug dosing in renal impairment by
-reducing the amount of the regular dose given
-extending the interval between regular doses
Pharmacological management of AKI
DHx
Withdraw potential nephrotoxics, consider future use
Dose adjustment in drugs/active metabolites that are renally excreted
Avoid
ACEi, NSADs, radiocontrast, aminoglycosides where possible
Monitor [drug]
Rehydration in AKI
1st line - 0.9% saline
Use NaHCO3 1.26% if hypovolemic AKI with metabolic acidosis
Aim for volume repletion
-250-500ml saline fluid boluses
Maintenance fluids
-monitor fluid balance
Diuretic use in CKD
Loop - if fluid overloaded/hyperkalemic/HTN
-urgent = furosemide IV
Thiazides ineffective in severe impairment (eGFR U30)
Potassium sparing diuretics - avoid due to hyperkalemia risk
ACEi, ARB use in CKD
Can be used but need to
-monitor BP
-titrate dose and monitor renal function
Creatinine can increase by 20% but this is not a absolute reason to discontinue
Do not use in
-bilateral renal artery stenosis
-renal artery stenosis in patient with only 1 functioning kidney
-widespread vascular disease => compromising blood flow
SGLT2 inh use in CKD
Dapagliflozin - can slow progression of CKD and lower risk of kidney failure
-add on to optimized standard care
Can use in eGFR 25 AND
-T2DM or
-uACR 22.6mg/mol+
BP control in CKD
CKD uACR U70 - 140/90
CKD uACR 70+ - 130/80
uACR U30 - regular HTN management
uACR 30+ - ACEi/ARB
Dietary salt restriction
Multiple HTN meds
Titrate up ACEi/ARB
Reduce dosing frequency where possible
Medications that affect K balance
Contain K - laxatives
K in serum - ACEi, ARB, spironolactone, NSAIDs
Prevent intracellular buffering of K - Bb, digoxin